Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Abstract Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results We administered 100 mg...

Full description

Bibliographic Details
Main Authors: Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Hotimah Masdan Salim, Gulinu Maimaituxun, Susumu Nishio, Yuriko Takagawa, Saori Hama, Tomomi Matsuura, Koji Yamaguchi, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike, Michio Shimabukuro, Masataka Sata
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Epicardial adipose tissue
SGLT2 inhibitors
Echocardiography
Online Access:http://link.springer.com/article/10.1186/s13098-017-0275-4

Internet

http://link.springer.com/article/10.1186/s13098-017-0275-4

Similar Items